景时（杭州）药业

Jingshi (Hangzhou) Pharmaceutical is a biopharmaceutical company focused on the discovery and development of innovative small molecule drugs, particularly in the field of oncology. Established in 2021, the company was founded by Dr. Zhang Xiaohu, who previously served as a key R&D executive at Betta Pharmaceuticals and played a significant role in the development of icotinib. Jingshi aims to address unmet medical needs in cancer treatment by developing next-generation targeted therapies that overcome resistance to existing drugs. The company's lead research efforts are directed toward fourth-generation EGFR inhibitors for non-small cell lung cancer. Headquartered in Hangzhou, China, Jingshi has secured significant early-stage funding from prominent investors such as Sequoia China and IDG Capital.